KalVista Pharmaceuticals (NASDAQ: KALV) surged 38.62% to close at $26.67 following the announcement of its acquisition by Italy’s Chiesi Group for $27 per share in cash. This significant price movement reflects investor optimism about the deal, despite potential regulatory hurdles and closing risks. The trading volume soared to 69.4 million shares, dramatically exceeding the three-month average of 2 million shares, indicating heightened interest in the stock.

The acquisition is particularly noteworthy as KalVista has struggled since its IPO in 2015, with a 66% decline in its stock price prior to this announcement. The deal aligns with Chiesi’s strategy to enhance its portfolio of rare disease treatments, particularly with KalVista’s recently approved oral therapy, EKTERLY, for hereditary angioedema. This could provide Chiesi with a competitive edge in the rare disease market, especially given KalVista’s previously high short interest of 40%.

For investors, the market is signaling a strong likelihood of the acquisition’s completion, making KALV a stock to watch as it transitions from a public entity to private ownership under Chiesi.

Source: fool.com